Taysha Gene Therapies, Inc. Common Stock
Symbol: TSHA (NASDAQ)
3.23
▼ (-0.77%) -0.025
Company Description:
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Key Stats
- Today's Open: $3.23
- Today's High: $3.305
- Today's Low: $3.195
- Today's Volume: 363.53K
- Yesterday Close: $3.25
- Yesterday High: $3.32
- Yesterday Low: $3.16
- Yesterday Volume: 2.52M
- Last Min Volume: 7.10K
- Last Min High: $3.235
- Last Min Low: $3.225
- Last Min VWAP: $3.23275
Company Profile
- Name: Taysha Gene Therapies, Inc. Common Stock
- Website: https://www.tayshagtx.com
- Listed Date: 2020-09-24
- Location: DALLAS, TX
- Market Status: Active
- CIK Number: 0001806310
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $886.58M
- Round Lot: 100
- Outstanding Shares: 272.79M
- Asset Type: CS
RECENT FILINGS FOR TSHA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 144 | View |
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-21 | 144 | View |
| 2025-08-21 | 144 | View |
| 2025-08-21 | 144 | View |
| 2025-08-21 | 144 | View |
| 2025-08-21 | 144 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-03 | SCHEDULE 13G | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
Latest News on TSHA